Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services for AI-Powered Cardiovascular Tests
CDIO Stock | USD 0.85 0.27 24.11% |
About 55% of Cardio Diagnostics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Cardio Diagnostics Holdings suggests that some traders are interested. Cardio Diagnostics' investing sentiment overview a quick insight into current market opportunities from investing in Cardio Diagnostics Holdings. Many technical investors use Cardio Diagnostics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Cardio |
Cardio Diagnostics announced their PrecisionCHD and EpiGen CHD tests have received final pricing determinations from CMS.
Read at businesswire.com
Cardio Diagnostics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Cardio Diagnostics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cardio Diagnostics Fundamental Analysis
We analyze Cardio Diagnostics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardio Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cardio Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Cardio Diagnostics is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Cardio Diagnostics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cardio Diagnostics stock to make a market-neutral strategy. Peer analysis of Cardio Diagnostics could also be used in its relative valuation, which is a method of valuing Cardio Diagnostics by comparing valuation metrics with similar companies.
Peers
Cardio Diagnostics Related Equities
IMMX | Immix Biopharma | 17.44 | ||||
CNSP | Cns Pharmaceuticals | 10.00 | ||||
ELEV | Elevation Oncology | 4.69 | ||||
PYXS | Pyxis Oncology | 3.70 | ||||
ZURA | Zura Bio | 0.80 | ||||
ZVSA | ZyVersa Therapeutics | 1.90 | ||||
CYTO | Altamira Therapeutics | 2.38 | ||||
PHIO | Phio Pharmaceuticals | 4.93 | ||||
SONN | Sonnet Biotherapeutics | 4.97 | ||||
ATNF | 180 Life | 5.70 |
Check out Cardio Diagnostics Hype Analysis, Cardio Diagnostics Correlation and Cardio Diagnostics Performance. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardio Diagnostics. If investors know Cardio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardio Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.30) | Revenue Per Share 0.002 | Quarterly Revenue Growth 3.562 | Return On Assets (0.98) | Return On Equity (2.93) |
The market value of Cardio Diagnostics is measured differently than its book value, which is the value of Cardio that is recorded on the company's balance sheet. Investors also form their own opinion of Cardio Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Cardio Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardio Diagnostics' market value can be influenced by many factors that don't directly affect Cardio Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardio Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardio Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.